Browse all categories:

An unholy triangle? Evidence, politics and uncertainty in drug policy

Professor Nutt’s talk explores the contributions of politics and science to decision making about alcohol and other drugs. Professor Nutt reveals how evidential uncertainties are used to strengthen the political rhetoric and how this process has led to the denial of clinical research and utility to the great detriment of millions of people for many  …


Clinical Insights - MDMA for Alcohol Use Disorder

Dr Ben Sessa – MDMA for Alcohol Use Disorder Dr Ben Sessa presents the preliminary data in an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder. At this stage, seven participants have completed the full 8-week MDMA-assisted psychotherapy course,  …


2019: A year of expansion in psychedelic research, industry, and deregulation

Public and scientific interest into psychedelic drugs has grown steadily over much of the last two decades, before an exponential increase in recent years. We contend that 2019, in particular, involved myriad notable changes in the science, industry, and deregulation of psychedelic drugs. However, it is becoming increasingly difficult for professionals to keep up-to-date on  …


Drug Science's 10th birthday at the House of Lords: past achievements and a bright future

Drug Science Patron Lord Nic Rea, hosted Drug Science committee members, trustees, and community supporters at House of Lords on Wednesday, celebrating ten years of achievements, and new initiatives in medical cannabis and psychedelic research. In the beautiful Cholmondeley Room of Westminster Palace, 150 of Drug Science’s supporters heard CEO David Badcock welcome guests and  …


Cannabis health information labels: why it’s time to have mandatory warnings as part of any legal cannabis market

Prof. Adam Winstock – Global Drug Survey 2019 As the tide of cannabis regulatory reform wafts through North America and beyond, it strikes me that the cannabis legalisation lobby started from a strong position. The weight of evidence and cogent arguments at their disposal to counter the totally unhelpful criminalisation of cannabis users was enormous.  …


Controversies in substance misuse in the older person

There are a range of issues facing us in relation to substance misuse in the older person: some are ongoing controversies and uncertainties; some are myths; and others certainties. Much of these issues are covered in depth in a new report published by the Royal College of Psychiatrists this year – Our Invisible Addicts. There  …

Class A is no solution to the problem of 'monkey dust'

The recent spate of headlines about the rising use of monkey dust drug in Stoke on Trent has led to calls to it to be made a Class A drug [from Class B where it/they are currently placed]. Whilst it is understandable that parents and local community groups would like to put an end to  …